Mitaclau (Desmopressin)

Desmopressin, the active ingredient in Mitaclau, is a vasopressin analog presented as a sublingual formulation for sublingual use. It selectively increases water reabsorption in the kidneys and is indicated for central diabetes insipidus, nocturnal enuresis, hemophilia A and von Willebrand disease in patients requiring antidiuretic or hemostatic therapy.

GNH USA supplies Mitaclau as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic and hemostatic pathways to manage disorders of water balance and coagulation. - Central diabetes insipidus: reduces excessive urine output by enhancing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes through improved water retention. - Hemophilia A: raises plasma factor VIII levels to aid clot formation. - Von Willebrand disease: increases von Willebrand factor release to improve platelet adhesion.

Desmopressin may be associated with a range of adverse reactions, most of which are mild and dose‑related.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Hyponatremia: mild reduction in serum sodium.

Serious or Rare Side Effects: - Severe hyponatremia: can lead to seizures or coma. - Water intoxication: excessive fluid retention causing edema. - Thromboembolic events: rare clot formation.

When prescribing Desmopressin, clinicians should consider several safety precautions to minimize risk. - Monitor serum sodium: check levels before and during therapy to detect hyponatremia. - Limit fluid intake: advise patients to restrict excessive water consumption. - Use caution in renal impairment: adjust therapy and monitor renal function. - Avoid in uncontrolled hypertension: assess blood pressure prior to initiation. - Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with carbamazepine: may reduce Desmopressin effectiveness. - Co‑administration with diuretics (especially thiazides): increases risk of hyponatremia. - Combination with NSAIDs: can exacerbate fluid retention and renal effects.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may potentiate hyponatremia. - Hormonal contraceptives: may affect fluid balance. - ACE inhibitors or ARBs: monitor blood pressure and electrolytes.